50 Chapter 2 REFERENCES 1. Barnholtz-Sloan JS, Yu C, Sloan AE, et al. A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol 2012; 14: 910–918. 2. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Journal of Clinical Oncology 2004; 22: 2865–2872. 3. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745–751. 4. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77: 655–661. 5. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007; 12: 884–898. 6. Khuntia D, Brown P, Li J, et al. Whole-brain radiotherapy in the management of brain metastasis. Journal of Clinical Oncology 2006; 24: 1295–1304. 7. Mehta MP. The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients. Neuro Oncol 2015; 17: 919–923. 8. Pinkham MB, Whitfield GA, Brada M. New developments in intracranial stereotactic radiotherapy for metastases. Clin Oncol 2015; 27: 316–323. 9. Grosshans DR, Meyers CA, Allen PK, et al. Neurocognitive function in patients with small cell lung cancer: effect of prophylactic cranial irradiation. Cancer 2008; 112: 589–595. 10. Vardy J, Dhillon HM, Pond GR, et al. Cognitive function and fatigue after diagnosis of colorectal cancer. Annals of Oncology 2014; 25: 2404–2412. 11. Mitchell T, Turton P. ‘Chemobrain’: Concentration and memory effects in people receiving chemotherapy - a descriptive phenomenological study. Eur J Cancer Care (Engl) 2011; 20: 539–548. 12. Reid-Arndt SA, Yee A, Perry MC, et al. Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. J Psychosoc Oncol 2009; 27: 415–434. 13. Griffith HR, Belue K, Sicola A, et al. Impaired financial abilities in mild cognitive impairment: a direct assessment approach. Neurology 2003; 60: 449–457. 14. Schimmel WCM, Gehring K, Eekers DBP, et al. Cognitive effects of stereotactic radiosurgery in adult patients with brain metastases: A systematic review. Adv Radiat Oncol 2018; 3: 568–581. 15. Tallet A V, Azria D, Barlesi F, et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiation oncology 2012; 7: 77. 16. Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2012; 2: 210–225. 17. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015 statement. Syst Rev 2015; 4: 1–9.
RkJQdWJsaXNoZXIy MTk4NDMw